GIP/GLP-1 Dual Receptor Agonist

Tirzepatide: Overview, Dosage, Side Effects & Research

FDA-approved dual-action peptide delivering up to 22% weight loss — the gold standard of prescription weight management.

Also known as: Mounjaro, Zepbound, LY3298176

20.9%
Weight Loss (24mg)
2539
Trial Participants
Phase 3
Not FDA Approved

What is Tirzepatide?

Tirzepatide is a once-weekly injectable that simultaneously activates GIP and GLP-1 receptors. GLP-1 activation suppresses appetite, slows gastric emptying, and enhances insulin secretion. GIP activation amplifies insulin response and may improve lipid metabolism and fat storage patterns. The dual mechanism produces greater weight loss than GLP-1-only drugs like semaglutide.

Typical Dose
10-15 mg
Frequency
Once weekly
Half-Life
~5 days
Administration
Subcutaneous injection (abdomen, thigh, upper arm)
Approval Status
FDA approved for T2D (Mounjaro, 2022) and obesity (Zepbound, 2023)
Legal Status
FDA approved. Requires prescription. Available via physician or telehealth provider.

Dosage Overview

LevelDose
Starting / Low2.5 mg
Typical / Maintenance10-15 mg
Maximum (studied)15 mg

Start at 2.5mg weekly for 4 weeks, then increase by 2.5mg every 4 weeks as tolerated. Maximum approved dose is 15mg weekly.

Full dosage guide with titration schedule →

Side Effects

Side EffectFrequency
Nauseacommon
Diarrheacommon
Vomitingcommon
Constipationcommon
Stomach paincommon
Decreased appetitecommon
Full side effects guide with management tips →

Clinical Research

Phase 3 (SURMOUNT-1)
Weight reduction in adults with obesity

Participants on 15mg tirzepatide lost an average of 22.5% of body weight over 72 weeks, compared to 2.4% for placebo.

Source: NEJM 2022; SURMOUNT-1
Phase 3 (SURPASS-2)
HbA1c reduction vs semaglutide in T2D

Tirzepatide 15mg reduced HbA1c by 2.46% vs 2.33% for semaglutide 1mg, and produced greater weight loss (12.4kg vs 6.2kg).

Source: NEJM 2021; SURPASS-2

Best Used For

Related Peptides

Exploring Retatrutide Access?

See how patients are accessing retatrutide through physician-supervised telehealth and compounding pharmacies.

Not FDA approved. Access requires physician oversight.

Affiliate links — we may earn a commission at no cost to you.

Compare Providers →

Frequently Asked Questions

What is the difference between Mounjaro and Zepbound?

Both contain tirzepatide (the same active ingredient) but are approved for different indications. Mounjaro is FDA-approved for type 2 diabetes management, while Zepbound is approved for chronic weight management in adults with obesity or overweight with a weight-related condition.

How much weight can I lose on Tirzepatide?

Clinical trials show an average of 22.5% body weight reduction at the highest dose (15mg) over 72 weeks. Individual results vary based on diet, activity, and adherence.

Is compounded Tirzepatide available?

Yes. During FDA-designated drug shortages, 503B compounding pharmacies can legally produce tirzepatide. Availability varies. Always verify the pharmacy's 503B status and request a Certificate of Analysis for purity verification.

How does Tirzepatide compare to Semaglutide (Ozempic/Wegovy)?

Tirzepatide (dual GIP/GLP-1) consistently outperforms semaglutide (GLP-1 only) on weight loss in head-to-head trials. The SURPASS-2 trial showed tirzepatide produced roughly twice the weight loss of semaglutide 1mg.

Where to Source Tirzepatide

Sourcing guidance, supplier vetting criteria, and price benchmarks.

View Sourcing Guide →

Related Reading